Sanofi scraps development of amcenestrant breast cancer treatment

PARIS — French healthcare company Sanofi said it would end the development program of amcenestrant, an estrogen receptor degrader aimed at curing breast cancer. Sanofi said the drug, which was used in combination with an agent known as palbociclib in the study, “did not meet the prespecified boundary for continuation in comparison with the control […]